The nation of Zimbabwe has declined a major US health deal valued at 367 million US dollars (£272m) over five years because of Washington's demand for sensitive data.
The decision came to light following a official document from December was disclosed, which showed President Emmerson Mnangagwa felt the deal was "unbalanced".
An official spokesperson has since explained that the United States was requesting health data for scientific study and profit but was not willing to share the benefits from future medical innovations.
"We will now turn to the challenging and unfortunate task of winding down our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had provided more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for further dialogue to find a deal suitable to both sides so the country's critical HIV treatment initiative can be sustained.
Broader Background
This rejection comes after a comparable case in Kenya, where a court blocked a similar health funding agreement following concerns were raised about the security of citizens' health data.
Since returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump claimed its spending was "wasteful" and his administration was pursuing government-to-government agreements to boost openness and responsibility.
According to statements, 16 nations in Africa have so far agreed to similar agreements, representing over $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe would have gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation would have delivered significant benefits for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy via American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, without any equivalent assurance of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that provided information," he stated.
"In essence, our nation would supply the raw materials for scientific discovery with no certainty that the end products would be accessible to our citizens if a future disease outbreak emerge."
National Interest and International Frameworks
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending structures previously set up through the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing system designed to manage potential global health emergencies.
"This system is intended to ensure that when a nation provides its information, the benefits – including vaccines and treatments – are shared equitably, not monopolised solely by those with the resources to develop them."
These objections over the US deal "are not meant as anti-American sentiment," he added.
"We encourage ongoing dialogue with our American counterparts on how future co-operation might be structured in a way that respects the sovereignty and interests of both nations."
Health Experts Reaction
Medical experts said it recognised the government's concerns, but suggested that negotiations need to persist given that a large portion of the nation's HIV programmes relied on external financing.
"If technical issues exist, including those relating to information security or implementation frameworks, these can often be addressed via technical clarification and negotiated safeguards," the group added.
The halted deal emphasises the ongoing debate between receiving crucial foreign assistance and protecting national sovereignty in an increasingly data-driven world.